openalexFrontiers in Immunology2026-07-24
The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS
Introduction The combination of enfortumab vedotin and pembrolizumab (EV+P) has revolutionized advanced urothelial carcinoma treatment, yet their combined real-world safety profile remains insufficiently characterized. This study aimed to quantitatively compare the adverse event…